Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli
Debilitating recurrent urinary tract infections (UTIs) are often associated with gastrointestinal colonisation by uropathogens, such as uropathogenic Escherichia coli (UPEC), suggesting that these populations might be a suitable target for the treatment and prevention of recurrent UTI. However, anti...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-02-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1528836 |
| _version_ | 1797677409090142208 |
|---|---|
| author | Sarah Larcombe Melanie L. Hutton Dena Lyras |
| author_facet | Sarah Larcombe Melanie L. Hutton Dena Lyras |
| author_sort | Sarah Larcombe |
| collection | DOAJ |
| description | Debilitating recurrent urinary tract infections (UTIs) are often associated with gastrointestinal colonisation by uropathogens, such as uropathogenic Escherichia coli (UPEC), suggesting that these populations might be a suitable target for the treatment and prevention of recurrent UTI. However, antimicrobial treatment is generally unable to prevent recurrent UTI, and often selects for multidrug resistant uropathogens in the gut, and causes dysbiosis of the gut, vaginal, and urinary microbiota. Of note, the globally-disseminated multi drug resistant UPEC lineage, ST131, is known to both persistently colonise the gut and the urinary tract, and is associated with antibiotic treatment failure, indicating the need for novel non-antibiotic therapeutics for the treatment of UTI. This study therefore presents hyperimmune bovine colostrum (HBC) as a suitable therapy for the treatment of UPEC gastrointestinal colonisation. This work demonstrates that the vaccination of pregnant cows with inactivated cells from a ST131 UPEC isolate results in a highly specific anti-UPEC HBC, and that this product is able to disrupt the gastrointestinal colonisation of ST131 UPEC in mice. |
| first_indexed | 2024-03-11T22:44:49Z |
| format | Article |
| id | doaj.art-66cf6212a35b4c0caa7a58d11aca9de0 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:44:49Z |
| publishDate | 2019-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-66cf6212a35b4c0caa7a58d11aca9de02023-09-22T08:38:24ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-02-0115250851310.1080/21645515.2018.15288361528836Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coliSarah Larcombe0Melanie L. Hutton1Dena Lyras2Monash UniversityMonash UniversityMonash UniversityDebilitating recurrent urinary tract infections (UTIs) are often associated with gastrointestinal colonisation by uropathogens, such as uropathogenic Escherichia coli (UPEC), suggesting that these populations might be a suitable target for the treatment and prevention of recurrent UTI. However, antimicrobial treatment is generally unable to prevent recurrent UTI, and often selects for multidrug resistant uropathogens in the gut, and causes dysbiosis of the gut, vaginal, and urinary microbiota. Of note, the globally-disseminated multi drug resistant UPEC lineage, ST131, is known to both persistently colonise the gut and the urinary tract, and is associated with antibiotic treatment failure, indicating the need for novel non-antibiotic therapeutics for the treatment of UTI. This study therefore presents hyperimmune bovine colostrum (HBC) as a suitable therapy for the treatment of UPEC gastrointestinal colonisation. This work demonstrates that the vaccination of pregnant cows with inactivated cells from a ST131 UPEC isolate results in a highly specific anti-UPEC HBC, and that this product is able to disrupt the gastrointestinal colonisation of ST131 UPEC in mice.http://dx.doi.org/10.1080/21645515.2018.1528836uropathogenic escherichia coliurinary tract infectionantibiotic resistancehyperimmune bovine colostrumimmunotherapeuticgastrointestinal colonisation |
| spellingShingle | Sarah Larcombe Melanie L. Hutton Dena Lyras Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli Human Vaccines & Immunotherapeutics uropathogenic escherichia coli urinary tract infection antibiotic resistance hyperimmune bovine colostrum immunotherapeutic gastrointestinal colonisation |
| title | Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli |
| title_full | Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli |
| title_fullStr | Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli |
| title_full_unstemmed | Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli |
| title_short | Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli |
| title_sort | hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic escherichia coli |
| topic | uropathogenic escherichia coli urinary tract infection antibiotic resistance hyperimmune bovine colostrum immunotherapeutic gastrointestinal colonisation |
| url | http://dx.doi.org/10.1080/21645515.2018.1528836 |
| work_keys_str_mv | AT sarahlarcombe hyperimmunebovinecolostrumreducesgastrointestinalcarriageofuropathogenicescherichiacoli AT melanielhutton hyperimmunebovinecolostrumreducesgastrointestinalcarriageofuropathogenicescherichiacoli AT denalyras hyperimmunebovinecolostrumreducesgastrointestinalcarriageofuropathogenicescherichiacoli |